MostCare Versus Echo-Doppler for Cardiac Output Measurement
NCT ID: NCT01678950
Last Updated: 2014-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2011-06-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Arterial Tone Influence on Cardiac Output Measured by PRAM
NCT03900546
Evaluation of a Non-invasive Cardiac Output Monitoring System.
NCT03178162
Evaluation of a Non-invasive Cardiac Output Monitoring System.
NCT03178097
The Consistency of Cardiac Output Measurements by Different Methods in VA-ECMO Patients
NCT04102072
Comparison of Different Cardiac Output Measurement Methods in Patients Undergoing Right Heart Catheterization
NCT05665218
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A. MostCare system data acquisition Before each CO measurement, the arterial pressure catheter and transducer quality will be assessed as follows: easy aspiration of 5 ml of blood easily re-injected without resistance; visual assessment of the quality of the arterial waveform contour; adequate response to the flush test (square wave). If necessary, the best position for the signal quality will be checked by extending the wrist and manipulating the catheter. For each determination of Echo-Doppler (and ThD-CO when applicable), a corresponding value for MostCare must be obtained by averaging the individual beats over the same time necessary to obtain the Echo-doppler-CO (and ThD-CO when applicable) measurements.
B. Echo-Doppler data acquisition (transoesophageal - TOE - or transthoracic - TTE - echo) Echo-Doppler-CO will be measured using the standard formula CSA x VTI (cross sectional area x velocity time integral x heart rate in ml/min). 2D measurement of the aortic annulus diameter allows calculation of the flow CSA which is then multiplied by the VTI (velocity time integral) of the Pulsed Doppler flow velocity profile across the aortic valve to determine the SV.
Other hemodynamic variables as an ancillary part of the study will compare shortening fraction (SF) or EF fraction from Echocardiography with CCE and dp/dt.
C. Thermodilution data acquisition (ThD-CO) (when applicable) Data coming from ThD pulmonary artery catheter (PAC) or a CVC + femoral artery catheter (transpulmonary thermodilution, PiCCO system) will be collected from the monitor itself or the system for patient monitoring used in the units.
For standard PAC-ThD-CO, five consecutive injections of 10 ml of 5% glucose cold solution will be randomly injected during respiratory cycle over a 5-min period. Thermodilution-CO (or PiCCO-CO) will be calculated as the average of the five measurements. All these 5 measurements will be collected.
MostCare, Echo-doppler (and Thermodilution when applicable) Change in ventilator parameters, sedation drugs, or fluid infusions or vasopressor dose will not be allowed during the acquisition time.
(\*) Study timing and procedure
For each patient CO determinations will be performed as follows:
Mandatory measurements:
• Baseline: (MostCare + Echo-doppler simultaneously, and MostCare + Echo-doppler + Thermodilution when applicable) = single comparison between techniques.
Recorded but not mandatory measurements (fitting to the therapeutic protocol used in each center):
• Pre- and post- treatment (fluid challenge, vasoactive drugs and inotropics changes) (MostCare + Echo-doppler simultaneously, and MostCare + Echo-doppler + Thermodilution when applicable) = dynamic comparison between techniques (two measures). This will allow a sub-analysis of CO (the trend of CO) changes, validity of trend, for both SV and CO before and after a therapeutic intervention.
Data to be collected:
Patient: demographic, anthropometric, pre-medical history, indication(s) for ICU admission; (cardiovascular diseases and cardiac function, respiratory diseases, etc...), severity scores (SAPS II, SOFA, ….).
All patients enrolled will be analysed in intention-to-treat even data recording failed. In this case, that would be a limit if any, for the tested technique.
Hemodynamic MostCare: SV, HR, CO, CCE, ∆P/∆T, ABPs, ABPd, ABPm. Other hemodynamic data: CVP, PaoP, SvO2, lactate,... Echocardiography: stroke volume, heart rate, cardiac output. Other hemodynamic variables are allowed to be collected by Echo according to the centre protocols and the experience of each centre.
Cardiac and vasoactive drugs dose or infusion rate will be collected: dobutamine, dopamine, norepinephrine, epinephrine, nitrates, beta-blockers, ACE-I,ecc.
Ventilatory: mechanical ventilation settings: mode of ventilation (CPAP, BiPAP, VC, PC), pressure support (if applicable), peak and plateau pressure, PEEP level, FiO2 oxygenation (SaO2, PaO2,…) ICU stay and outcome: morbidity (number and type of complications), length of stay, mortality.
(\*) Statistical analysis and methodology, number of patients to be enrolled, duration of the study:
Collected data will be copied on an excel file to be properly independently analyzed with a statistical software. Correlation tests (Spearman or Pearson), Student paired t-test, and Bland-Altman analysis will be applied. A minimum of 30 patients per centre will be enrolled in the study in a period of 18 months.
This "minimum number" of patients is mandatory as: 1) the enrollment of 30 patients per centre eliminates the potential bias that may occur when few data come from a single centre, 2) minimum 300 patients enrolled represents a suitable number to obtain the "statistical power" necessary to validate the comparison between the different methods, and 3) further analysis and comparisons in subgroup of patients having similar clinical settings can be performed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients requiring an echocardiographic evaluation - Transthoracic Echocardiographic Evaluation (TEE)or Transesophageal Echocardiographic Evaluation (TOE) - as a routine need or in the context of Acute Cardiocirculatory failure with suspected implication of cardiac dysfunction or Acute Respiratory failure and suspicion of cardiac failure.
* \*When a pulmonary artery catheter (PAC, standard bolus thermodilution, ThD) is used or a central venous catheter linked with a femoral artery catheter to measure the transpulmonary thermodilution (PiCCO system: Continuous pulse contour cardiac analysis), the comparison will be done as a secondary end point of the protocol.
* The point n.3 is optional
Exclusion Criteria
pathologies that could affect the quality and reliability of the arterial signal (aortic valve pathologies, aortic aneurysms) and arrhythmias that generate hemodynamic instability (i.e., variations in mean BP measurements \> 10%); poor quality of the arterial pressure signal after a standard flush test (i.e., over-damped or under-damped arterial trace).
* Related to Echo-Doppler: non-feasibility to obtain a fulfilled quality of the images.
* Patients younger than 18.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Ospedaliera Universitaria Senese
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sabino Scolletta
MD, Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Anesthesiology & Intensive Care - Lariboisière University Hospital University Paris 7 Diderot. France
Paris, Paris, France
Department of Anaesthesia and Intensive Care, Torrette University Hospital
Ancona, Ancona, Italy
Intensive Care Unit, Santa Maria Annunziata Hospital
Florence, Florence, Italy
Department of Cardiovascular Anesthesia and Intensive Care, Careggi University Hospital, Italy
Florence, Florence, Italy
Anaesthesia and Intensive Care Unit, S. Giovanni di Dio - Torregalli Hospital
Florence, Florence, Italy
Department of Anaesthesia and Intensive Care, Ospedali Riuniti Foggia University Hospital
Foggia, Foggia, Italy
Cardio-Thoracic-Vascular Anaesthesia and Intensive Care, San Raffaele University Hospital
Milan, Milan, Italy
Department of Anaesthesia and Intensive Care, Pisa University Hospital
Pisa, Pisa, Italy
Cardiovascular Anesthesia, Policlinico Umberto I°
Rome, Rome, Italy
Department of Anaesthesia and Intensive Care, Siena University Hospital
Siena, Siena, Italy
Policlinico Universitario Padova
Padua, , Italy
Ospedale S. Antonio Abate di Pontremoli
Pontremoli, , Italy
of Anesthesia, Critical Care and Pain Medicine, Hospital Universitario de la Ribera
Valencia, Valencia, Spain
(Cardiothoracic Anaesthesia, Heart and Lung Centre, New Cross Hospital
Wolverhampton, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRAM2012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.